Urinary level of homovanillic acid and mercury in autistic children

Toxicological and Environmental Chemistry

Volumn 93, Issue 1, 2011, Pages 199-206

  Kaluzna Czaplińska, Joanna ^a   Socha, Ewa ^a   Michalska, Monika ^a   Rynkowski, Jacek ^a  

^a LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Autism; Homovanillic acid (hva); Mercury aspect

Indexed keywords

AUTISM; AUTISTIC CHILDREN; HOMOVANILLIC ACID; MERCURY ASPECT; NERVOUS SYSTEM; ROUTINE ANALYSIS; UNDESIRABLE EFFECTS;

ACIDS; BIOMOLECULES; BODY FLUIDS; BRAIN; METABOLISM; METABOLITES;

MERCURY (METAL);

BRAIN; CHILD HEALTH; ENZYME ACTIVITY; MERCURY (ELEMENT); METABOLITE; NEUROLOGY;

EID: 78649404232     PISSN: 02772248     EISSN: 10290486     Source Type: Journal    
DOI: 10.1080/02772248.2010.498376     Document Type: Article

References (34)

1. Adams, J.B., M. Baral, E. Geis, J. Mitchell, J. Ingram, A. Hensley, I. Zappia, et al. 2009. The severity of autism is associated with toxic metal body burden and red blood cell glutathione levels. Journal of Toxicology 2009: 1-7.
2. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association.
3. Barthelemy, C., N. Bruneau, J.M. Cottet-Eymard, J. Domenech-Jouve, B. Garreau, G. Lelord, J.P. Muh, and L. Peyrin. 1988. Urinary free and conjugated catecholamines and metabolites in autistic children. Journal of Autism and Developmental Disorders 18: 583-91.
4. Bernard, S., A. Enayati, and L. Redwood. 2001. Autism: A novel form of Mercury poisoning. Medical Hypotheses 56: 462-71.
5. Collins, R.A. 2006. Biomedical intervention and prospects for recovery from autism. Biomedical Scientist 50: 954-79.
6. Cory-Slechta, D.A. 2005. Studying toxicants are single chemicals: Does this strategy adequately identify neurotoxic risk? Neurotoxicology 26: 491-510.
7. Counter, S.A., and L.H. Buchanan. 2004. Mercury exposure in children: A review. Toxicology and Applied Pharmacology 198: 209-30.
8. Croonenberghs, J., L. Delmeire, R. Verkerk, A. Lin, A. Meskal, H. Neels, M. Planken, et al. 2000. Peripheral markers of serotonergic and noradrenergic function in post-pubertal, Caucasian males with autistic disorder. Neuropsychopharmacology 22: 275-83.
9. Durczok, A., R. Szkilnik, R. Brus, P. Nowak, L. Labus, J. Konecki, K. Drabek, G. Kuballa, W. Rycerski, and K. Mengel. 2002. Effect of organic mercury exposure during early stage of ontogenic development on the central dopaminergic system in adult rats. Polish Journal of Environmental Studies 11: 307-14.
10. Faro, L.R.F., J.L.M. Nascimento, M. Alfonso, R. Duran, and C.W. Picanco-Diniz. 1997. Effects of methyl mercury on the in vivo release of dopamine and its acidic metabolites DOPAC and HVA from striatum of rats. Ecotoxicology and Environmental Safety 38: 95-8.
11. Faro, L.R.F., J.L.M. Nascimento, J.M. San Jose, M. Alfonso, and R. Duran. 2000. Intrastriatal administration of methylmercury increases in vivo dopamine release. Neurochemical Research 25: 225-9.
12. Garnier, C., E. Comoy, C. Barthelemy, I. Leddet, B. Garreau, J.P. Muh, and G. Lelord. 1986. Dopamine-beta-hydroxylase (DBH) and homovanillic acid (HVA) in autistic children. Journal of Autism and Developmental Disorders 16: 23-9.
13. Garreau, B., C. Barthelemy, J. Jouve, N. Bruneau, J.P. Muh, and G. Lelord. 1988.Urinary homovanillic acid levels of autistic children. Developmental medicine and child neurology 30: 93-8.
14. Geier, M.R., and A.D. Geier. 2003. Thimerosal in childhood vaccines, neurodevelopment disorders, and heart disease in the United States. Journal of American Physicians and Surgeons 8: 6-11.
15. Geier, A.D., and M.R. Geier. 2006. Early downward trends in neurodevelopmental disorders following removal of thimerosal - containing vaccines. Journal of American Physicians and Surgeons 11: 8-13.
16. Green, J.M.D. 2006. Detoxification through chelation therapy. Autism Research Review International 20: 3.
17. Heron, N., and J. Golding. 2004. Thimerosal exposure in infants and developmental disorders: A prospective cohort study in the United Kingdom does not support a causal association. Pediatrics 114: 577-83.
18. Hertz-Picciotto, I., P.G. Green, L. Delwiche, R. Hansen, Ch. Walker, and I.N. Pessah. 2010. Blood mercury concentrations in CHARGE study children with and without autism. Environmental Health Perspectives 118: 161-6.
19. Hviid, A., M. Stellfeld, J. Wohlfahrt, and M. Melbye. 2003. Association between thimerosal- containing vaccine and autism. The Journal of the American Medical Association 290: 1763-6
20. Jarosinska, D., L. Barregard, M. Biesiada, M. Muszynska-Graca, B. Dabkowska, B. Denby, J. Pacyna, J. Fudala, and U. Zielonka. 2006. Urinary mercury in adults in Poland living near a chloralkali plant. Science of the Total Environment 368: 335-43.
21. Kaluzna-Czaplinska, J., W. Grys, and J. Rynkowski. 2008. Neurotoxic factors in the child's environment as a reason for developmental disorders in autism. Nowa Pediatria 3: 50-7.
22. Kaluzna-Czaplinska, J., E. Socha, M. Michalska, W. Grys, A. Rozetti-Szymanska, J. Wojcik, and J. Rynkowski. 2009. The level of homovanillic acid in urine of autistic children. Medycyna Rodzinna 2: 48-52.
23. Madsen, K.M., M.B. Lauritsen, C.B. Pedersen, P. Thorsen, A.M. Plesner, P.H. Andersen, and P.B. Mortensen. 2003. Thimerosal and the occurrence of autism: Negative ecological evidence from Danish population-based data. Pediatrics 112: 604-6.
24. Minderaa, R.B., G.M. Anderson, F.R. Volkmar, G.W. Akkerhuis, and D.J. Cohen. 1989. Neurochemical study of dopamine functioning in autistic and normal subjects. Journal of the American Academy of Child and Adolescent Psychiatry 28: 190-4.
25. Narita, N., M. Kato, M. Tazoe, K. Miyazaki, M. Narita, and N. Okado. 2002. Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: Putative animal models for autism. Pediatric Research 52: 576-9.
26. Nelson, K.B., and M.L. Bauman. 2003. Thimerosal and autism? Pediatrics 111: 674-9.
27. Pabello, N.G., and D.A. Lawrence. 2006. Neuroimmunotoxicology: Modulation of neuroimmune networks by toxicants. Clinical Neuroscience Research 6: 69-85.
28. Parker, S.K., B. Schwartz, J. Todd, and L.K. Pickering. 2004. Thimerosal-containing vaccines and autistic spectrum disorder: A critical review of published original data. Pediatrics. 114: 793-804.
29. Pichichero, M.E., A. Gentile, N. Giglio, V. Umido, T. Clarkson, E. Cernichiari, G. Zareba, et al. 2008. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics 121: 208-14.
30. Previc, F.H. 2007. Prenatal influences on brain dopamine and their relevance to the rising incidence of autism. Medical Hypotheses 68: 46-60.
31. Stehr-Green, P., P. Tull, M. Stellfeld, P.B. Mortenson, and D. Simpson. 2003. Autism and thimerosal-containing vaccines: Lack of consistent evidence for an association. American Journal of Preventive Medicine 25: 101-6.
32. Stier, P.A., and R.A. Gordon. 1998. Psychiatric aspects of mercury poisoning. Medical Update for Psychiatrists 3: 144-7.
33. Verstraeten, T., R.L. Davis, F. DeStefano, T.A. Lieu, P.H. Rhodes, S.B. Black, H. Shinefield, and R.T. Chen. 2003. Safety of thimerosal-containing vaccines: A two-phased study of computerized health maintenance organization databases. Pediatrics 112: 1039-48.
34. Zahir, F., S.J. Rizwi, S.K. Hag, and R.H. Khan. 2005. Low dose mercury toxicity, human health. Environmental Toxicology and Pharmacology 20: 351-60.